4. Эйкозаноиды (обзорная статья). Козатриеновой кислоты, резолвины, протектины, марезин и эндоканнабиноиды оказывают противовоспалительное и цитопро
 Скачать 391.45 Kb.
|
|
Autoimmun Rev. 2011 May;10(7):369-74. doi: 10.1016/j.autrev. 2010.12.006. Epub 2010 Dec 30. 3. Martin P, Nunan R. Cellular and molecu- lar mechanisms of repair in acute and chronic wound healing. Br J Dermatol. 2015 Aug;173(2):370-8. doi: 10.1111/bjd.13954. Epub 2015 Jul 14. 4. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011 Dec 8;365(23):2205-19. doi: 10.1056/ NEJMra1004965. 5. Samadi AK, Bilsland A, Georgakilas AG, et al. A multi-targeted approach to suppress tumor-promoting inflammation. Semin Cancer Biol. 2015 Dec;35 Suppl:S151-84. doi: 10.1016/j.semcancer.2015.03.006. Epub 2015 May 5. 6. Robinson WH, Lepus CM, Wang Q, et al. Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis. Nat Rev Rheumatol. 2016 Oct;12(10):580-92. doi: 10.1038/nrrheum.2016.136. [Epub 2016 Aug 19] 7. Ridker PM, Lü scher TF. Anti-inflamma- tory therapies for cardiovascular disease. Eur Heart J. 2014 Jul 14;35(27):1782-91. doi: 10. 1093/eurheartj/ehu203. Epub 2014 May 26. 8. Minghetti L. Role of COX-2 in inflamma- tory and degenerative brain diseases. Subcell Biochem. 2007;42:127-41. 9. Kotas ME, Medzhitov R. Homeostasis, inflammation, and disease susceptibility. Cell. 2015 Feb 26;160(5):816-27. doi: 10.1016/j. cell.2015.02.010. 10. Van Dyke TE, Kornman KS. Inflammation and factors that may regulate inflammatory response. J Periodontol. 2008 Aug;79(8 Suppl):1503-7. doi: 10.1902/ jop.2008.080239. 11. Nathan C, Ding A. Nonresolving inflam- mation. Cell. 2010 Mar 19;140(6):871-82. doi: 10.1016/j.cell.2010.02.029. 12. Freire MO, Van Dyke TE. Natural resolu- tion of inflammation. Periodontol 2000. 2013 Oct;63(1):149-64. doi: 10.1111/prd.12034. 13. Kumar H, Kawai T, Akira S. Pathogen recognition by the innate immune system. Int Rev Immunol. 2011 Feb;30(1):16-34. doi: 10.3109/08830185.2010.529976. 14. Martinon F, Tschopp J. NLRs join TLRs as innate sensors of pathogens. Trends Immunol. 2005 Aug;26(8):447-54. 15. Serhan CN. Resolution phase of inflam- mation: novel endogenous anti-inflammatory and proresolving lipid mediators and path- ways. Annu Rev Immunol. 2007;25:101-37. 16. Braga TT, Agudelo JS, Camara NO. Macrophages During the Fibrotic Process: M2 as Friend and Foe. Front Immunol. 2015 Nov 25;6:602. doi: 10.3389/fimmu. 2015. 00602. eCollection 2015. 17. Насонов ЕЛ, Александрова ЕН, Авдее- ва АС, Рубцов ЮП. Т-регуляторые клетки при ревматоидном артрите. Научно-прак- тическая ревматология. 2014;52(4):430–7. [Nasonov EL, Aleksandrova EN, Avdeeva AS, Rubtsov YuP. T-regulatory cells in rheuma- toid arthritis. Nauchno-prakticheskaya revma- tologiya = Rheumatology Science and Practice. 2014;52(4):430–7. (In Russ.)]. DOI:10.14412/1995-4484-2014-430-437 18. Crean D, Godson C. Specialised lipid mediators and their targets. Semin Immunol. 2015 May;27(3):169-76. doi: 10.1016/j.smim. 2015.05.002. Epub 2015 Jun 3. 19. Weylandt KH. Docosapentaenoic acid derived metabolites and mediators – The new world of lipid mediator medicine in a nut- shell. Eur J Pharmacol. 2016 Aug 15;785: 108-15. doi: 10.1016/j.ejphar.2015.11.002. Epub 2015 Nov 10. 20. Dennis EA, Cao J, Hsu YH, et al. Phospholipase A2 enzymes: physical struc- ture, biological function, disease implication, chemical inhibition, and therapeutic inter- vention. Chem Rev. 2011 Oct 12;111(10): 6130-85. doi: 10.1021/cr200085w. Epub 2011 Sep 12. 21. Dennis EA, Norris PC. Eicosanoid storm in infection and inflammation. Nat Rev Immunol. 2015 Aug;15(8):511-23. doi: 10.1038/ nri3859. Epub 2015 Jul 3. 22. Buczynski MW, Dumlao DS, Dennis EA. Thematic Review Series: Proteomics. An integrated omics analysis of eicosanoid biology. J Lipid Res. 2009 Jun;50(6):1015-38. doi: 10.1194/jlr.R900004-JLR200. Epub 2009 Feb 24. 23. Newcomer ME, Gilbert NC. Location, location, location: compartmentalization of early events in leukotriene biosynthesis. J Biol Chem. 2010 Aug 13;285(33):25109-14. doi: 10.1074/jbc.R110.125880. Epub 2010 May 27. 24. Korbecki J, Baranowska-Bosiacka I, Gutowska I, Chlubek D. Cyclooxygenase pathways. Acta Biochim Pol. 2014;61(4): 639-49. Epub 2014 Oct 23. 25. Ueno N, Takegoshi Y, Kamei D, et al. Coupling between cyclooxygenases and ter- minal prostanoid synthases. Biochem Biophys Res Commun. 2005 Dec 9;338(1):70-6. Epub 2005 Aug 29. 26. Ganesh T. Prostanoid receptor EP2 as a therapeutic target. J Med Chem. 2014 Jun 12;57(11):4454-65. doi: 10.1021/jm401431x. Epub 2013 Dec 4. 27. Chen C. COX-2's new role in inflamma- tion. Nat Chem Biol. 2010 Jun;6(6):401-2. doi: 10.1038/nchembio.375. 28. Harizi H. Epigenetic regulations of inflammatory cyclooxygenase-derived prostanoids: molecular basis and pathophysi- ological consequences. Mediators Inflamm. 2015;2015:841097. doi: 10.1155/2015/ 841097. Epub 2015 Apr 6. 29. Brzozowski T, Konturek PC, Konturek SJ, et al. Role of prostaglandins in gastroprotec- tion and gastric adaptation. J Physiol Pharmacol. 2005 Sep;56 Suppl 5:33-55. 30. Ellinsworth DC, Shukla N, Fleming I, Jeremy JY. Interactions between В, thromboxane/prostaglandin (TP) recep- tors, and endothelium-derived hyperpolariza- tion. Cardiovasc Res. 2014 Apr 1;102(1):9-16. doi: 10.1093/cvr/cvu015. Epub 2014 Jan 26. 31. Sellers MM, Stallone JN. Sympathy for the devil: the role of thromboxane in the regulation of vascular tone and blood pres- sure. Am J Physiol Heart Circ Physiol. 2008 May;294(5):H1978-86. doi: 10.1152/ajp- heart.01318.2007. Epub 2008 Feb 29. 32. Gryglewski RJ. Prostacyclin among prostanoids. Pharmacol Rep. 2008 Jan-Feb; 60(1):3-11. 33. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem. 1996 Dec 27;271(52):33157-60. 34. Chen L, Yang G, Grosser T. Prostanoids and inflammatory pain. Prostaglandins Other Lipid Mediat. 2013 Jul-Aug;104-105:58-66. doi: 10.1016/j.prostaglandins.2012.08.006. Epub 2012 Sep 3. 35. Rossitto M, Ujjan S, Poulat F, Boizet- Bonhoure B. Multiple roles of the prostaglandin D2 signaling pathway in repro- duction. Reproduction. 2015 Jan;149(1):R49-58. doi: 10.1530/REP-14-0381. Epub 2014 Sep 30. 36. Le Loupp AG, Bach-Ngohou K, Bettan A, et al. Dual role for prostaglandin D2 in intes- tinal epithelial homeostasis. Med Sci (Paris). 2015 Jun-Jul;31(6-7):617-21. doi: 10.1051/ medsci/20153106014. Epub 2015 Jul 7. 37. Basu S. Bioactive eicosanoids: role of prostaglandin F(2 α) and В in inflammation and oxidative stress related pathology. Mol Cells. 2010 Nov;30(5):383-91. doi: 10.1007/s10059-010-0157-1. Epub 2010 Nov 18. 38. Fan C, Katsuyama M, Wei H, et ЛИТЕРАТУРА СОВ М Е Н НА ЯРЕ В МАТ О ЛОГИ Я № 4 ’ 1 ОБЗОРЫ anti-inflammatory and neu- roprotective actions of PPAR-gamma ago- nists. Front Biosci. 2008 Jan 1;13:1813-26. 40. Malmsten CL. Prostaglandins, thrombo- xanes, and leukotrienes in inflammation. Am J Med. 1986 Apr 28;80(4B):11-7. 41. Samuelsson B, Dahlen SE, Lindgren JA, et al. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science. 1987 Sep 4;237(4819):1171-6. 42. Mashima R, Okuyama T. The role of lipoxygenases in pathophysiology; new insights and future perspectives. Redox Biol. 2015 Dec;6:297-310. doi: 10.1016/j.redox. 2015.08.006. Epub 2015 Aug 7. 43. Kanaoka Y, Boyce JA. Cysteinyl leukotrienes and their receptors; emerging concepts. Allergy Asthma Immunol Res. 2014 Jul;6(4):288-95. doi: 10.4168/aair.2014.6. 4.288. Epub 2014 May 27. 44. Noguchi K, Okubo M. Leukotrienes in nociceptive pathway and neuropathic/inflam- matory pain. Biol Pharm Bull. 2011;34(8): 1163-9. 45. Feltenmark S, Gautam N, Brunnströ m A, et al. Eoxins are proinflammatory arachidonic acid metabolites produced via the 15-lipoxygenase-1 pathway in human eosinophils and mast cells. Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):680-5. doi: 10.1073/pnas.0710127105. Epub 2008 Jan 9. 46. Jin J, Zheng Y, Boeglin WE, Brash AR. Biosynthesis, isolation, and NMR analysis of leukotriene A epoxides: substrate chirality as a determinant of the cis or trans epoxide con- figuration. J Lipid Res. 2013 Mar;54(3):754-61. doi: 10.1194/jlr.M033746. Epub 2012 Dec 13. 47. Claesson HE, Griffiths WJ, Brunnströ m A, et al. Hodgkin Reed-Sternberg cells express 15-lipoxygenase-1 and are putative producers of eoxins in vivo: novel insight into the inflammatory features of classical Hodgkin lymphoma. FEBS J. 2008 Aug;275(16):4222-34. doi: 10.1111/j.1742-4658.2008.06570.x. Epub 2008 Jul 18. 48. Nigam S, Zafiriou MP, Deva R, et al. Structure, biochemistry and biology of hepoxilins: an update. FEBS J. 2007 Jul;274(14):3503-12. Epub 2007 Jul 2. 49. Pace-Asciak CR. Pathophysiology of the hepoxilins. Biochim Biophys Acta. 2015 Apr;1851(4):383-96. doi: 10.1016/j.bbalip. 2014.09.007. Epub 2014 Sep 19. 50. Douda D, Grasemann H, Pace-Asciak C, Palaniyar N. A lipid mediator hepoxilin A3 is a natural inducer of neutrophil extracellular traps in human neutrophils. Mediators Inflamm. 2015;2015:520871. doi: 10.1155/ 2015/520871. Epub 2015 Feb 16. 51. Panigrahy D, Kaipainen A, Greene ER, Huang S. Cytochrome P450-derived eicosanoids: the neglected pathway in cancer. Cancer Metastasis Rev. 2010 Dec;29(4):723-35. doi: 10.1007/s10555-010-9264-x. 52. Capdevila JH, Falck JR, Harris RC. Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxyge- nase. J Lipid Res. 2000 Feb;41(2):163-81. 53. Makita K, Falck JR, Capdevila JH. Cytochrome P450, the arachidonic acid cas- cade, and hypertension: new vistas for an old enzyme system. FASEB J. 1996 Nov;10(13): 1456-63. 54. Oni-Orisan A, Alsaleh N, Lee CR, Seubert JM. Epoxyeicosatrienoic acids and cardioprotection: the road to translation. J Mol Cell Cardiol. 2014 Sep;74:199-208. doi: 10.1016/ j.yjmcc.2014.05.016. Epub 2014 Jun 2. 55. Deng Y, Theken KN, Lee CR. Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of car- diovascular inflammation. J Mol Cell Cardiol. 2010 Feb;48(2):331-41. doi: 10.1016/j.yjmcc. 2009.10.022. Epub 2009 Nov 3. 56. Chandrasekharan JA, Sharma-Walia N. Lipoxins: nature's way to resolve inflamma- tion. J Inflamm Res. 2015 Sep 30;8:181-92. doi: 10.2147/JIR.S90380. eCollection 2015. 57. Trostel J, Garcia GE. Endogenous Inhibitors of Kidney Inflammation. J Nephrol Res. 2015 Oct;1(2):61-68. 58. Gilroy DW. The role of aspirin-triggered lipoxins in the mechanism of action of aspirin. Prostaglandins Leukot Essent Fatty Acids. 2005 Sep-Oct;73(3-4):203-10. 59. Brzozowski T, Konturek PC, Pajdo R, et al. Physiological mediators in nonsteroidal anti- inflammatory drugs (NSAIDs)-induced impairment of gastric mucosal defense and adaptation. Focus on nitric oxide and lipox- ins. J Physiol Pharmacol. 2008 Aug;59 Suppl 2:89-102. 60. Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature. 2014 Jun 5;510(7503):92-101. doi: 10.1038/ nature13479. 61. Headland SE, Norling LV. The resolution of inflammation: Principles and challenges. Semin Immunol. 2015 May;27(3):149-60. doi: 10.1016/j.smim.2015.03.014. Epub 2015 Apr 22. 62. Serhan CN, Dalli J, Colas RA, et al. Protectins and maresins: New pro-resolving families of mediators in acute inflammation and resolution bioactive metabolome. Biochim Biophys Acta. 2015 Apr;1851(4):397-413. doi: 10.1016/j.bbalip.2014.08.006. Epub 2014 Aug 17. 63. Serhan CN, Dalli J, Karamnov S, et al. Macrophage proresolving mediator maresin 1 stimulates tissue regeneration and controls pain. FASEB J. 2012 Apr;26(4):1755-65. doi: 10.1096/fj.11-201442. Epub 2012 Jan 17. 64. Zurier RB, Burstein SH. Cannabinoids, inflammation, and fibrosis. FASEB J. 2016 Jul 19. pii: fj.201600646R. [Epub ahead of print] 65. Rouzer CA, Marnett LJ. Endocannabinoid oxygenation by cyclooxy- genases, lipoxygenases, and cytochromes P450: cross-talk between the eicosanoid and endocannabinoid signaling pathways. Chem Rev. 2011 Oct 12;111(10):5899-921. doi: 10.1021/cr2002799. Epub 2011 Sep 19. 66. Turcotte C, Chouinard F, Lefebvre JS , Flamand N. Regulation of inflammation by cannabinoids, the endocannabinoids 2-arachidonoyl-glycerol and arachidonoyl- ethanolamide, and their metabolites. J Leukoc Biol. 2015 Jun;97(6):1049-70. doi: 10.1189/jlb.3RU0115-021R. Epub 2015 Apr 15. 67. Hermanson DJ, Gamble-George JC, Marnett LJ, Patel S. Substrate-selective COX-2 inhibition as a novel strategy for thera- peutic endocannabinoid augmentation. Trends Pharmacol Sci. 2014 Jul;35(7):358-67. doi: 10.1016/j.tips.2014.04.006. Epub 2014 May 18. 68. Новиков АА, Александрова ЕН, Диа- троптова МА, Насонов ЕЛ. Роль цитоки- нов в патогенеза ревматоидного артрита. Научно-практическая ревматология. 2010; 48(2):71-82. [Novikov AA, Aleksandrova EN, Diatroptova MA, Nasonov EL. Role of cytokines in the pathogenesis of rheumatoid arthritis. Nauchno-prakticheskaya revma- tologiya = Rheumatology Science and Practice. 2010;48(2):71-82. (In Russ.)]. DOI:10.14412/ 1995-4484-2010-1420 69. Sommerfelt RM, Feuerherm AJ, Skuland T, Johansen B. Cytosolic phospholi- pase A2 modulates TLR2 signaling in synovio- cytes. PLoS One. 2015 Apr 20;10(4):e0119088. doi: 10.1371/journal.pone.0119088. eCollection 2015. 70. Yousefi B, Jadidi-Niaragh F, Azizi G, et al. The role of leukotrienes in immunopathogene- sis of rheumatoid arthritis. Mod Rheumatol. 2014 Mar;24(2):225-35. doi: 10.3109/14397595. 2013.854056. 71. Stanczyk J, Kowalski ML. The role of cyclooxygenase and prostaglandins in the pathogenesis of rheumatoid arthritis. Pol Merkur Lekarski. 2001 Nov;11(65):438-43. 72. Sakata D, Yao C, Narumiya S. Prosta- glandin E2, an immunoactivator. J Pharmacol Sci. 2010;112(1):1-5. Epub 2010 Jan 6. 73. Akaogi J, Nozaki T, Satoh M, Yamada H. Role of PGE2 and EP receptors in the patho- genesis of rheumatoid arthritis and as a novel therapeutic strategy. Endocr Metab Immune Disord Drug Targets. 2006 Dec;6(4):383-94. 74. Hikiji H, Takato T, Shimizu T, Ishii S. The roles of prostanoids, leukotrienes, and platelet-activating factor in bone metabolism and disease. Prog Lipid Res. 2008 Mar;47(2):107-26. doi: 10.1016/j.plipres. 2007.12.003. Epub 2008 Jan 8. 75. Wang MJ, Huang Y, Huang RY, et al. Determination of role of thromboxane A2 in rheumatoid arthritis. Discov Med. 2015 Jan; 19(102):23-32. 76. Tuncer S, Banerjee S. Eicosanoid pathway in colorectal cancer: Recent updates. World J Gastroenterol. 2015 Nov 7;21(41):11748-66. doi: 10.3748/wjg.v21.i41.11748. 77. Gui H, Tong Q, Qu W, et al. The endo- cannabinoid system and its therapeutic impli- cations in rheumatoid arthritis. Int Immunopharmacol. 2015 May;26(1):86-91. doi: 10.1016/j.intimp.2015.03.006. Epub 2015 Mar 16. 78. Hashimoto A, Hayashi I, Murakami Y, et al. Antiinflammatory mediator lipoxin A4 and its receptor in synovitis of patients with rheuma- toid arthritis. J Rheumatol. 2007 Nov;34(11): 2144-53. Epub 2007 Oct 1. 79. Fukuda S, Kohsaka H, Takayasu A, et al. Cannabinoid receptor 2 as a potential thera- peutic target in rheumatoid arthritis. BMC Musculoskelet Disord. 2014 Aug 12;15:275. doi: 10.1186/1471-2474-15-275. 80. Arnardottir HH, Dalli J, Norling LV, СОВ М Е Н НА ЯРЕ В МАТ О ЛОГИ Я № 4 ’ 1 ОБЗОРЫ 86Поступила 17.09.2016 Исследование не имело спонсорской поддержки. Авторы несут полную ответственность за предоставление окончательной версии рукописи в печать. Все авторы принимали участие в разработке концепции статьи и написании рукописи. Окончательная версия рукописи была одобрена всеми авторами al. Resolvin D3 Is Dysregulated in Arthritis and Reduces Arthritic Inflammation. J Immunol. 2016 Aug 17. pii: 1502268. [Epub ahead of print] 81. Zhang W, Ouyang H, Dass CR, Xu J. Current research on pharmacologic and regenerative therapies for osteoarthritis. Bone Res. 2016 Mar 1;4:15040. doi: 10.1038/ boneres.2015.40. eCollection 2016. 82. He W, Pelletier JP, Martel-Pelletier J, et al. Synthesis of interleukin 1beta, tumor necrosis factor-alpha, and interstitial collagenase (MMP-1) is eicosanoid dependent in human osteoarthritis synovial membrane explants: interactions with antiinflammatory cytokines. J Rheumatol. 2002 Mar;29(3):546-53. 83. Wang P, Guan PP, Guo C, et al. Fluid shear stress-induced osteoarthritis: roles of cyclooxygenase-2 and its metabolic products in inducing the expression of proinflammato- ry cytokines and matrix metalloproteinases. FASEB J. 2013 Dec;27(12):4664-77. doi: 10.1096/fj.13-234542. Epub 2013 Aug 20. 84. Gosset M, Berenbaum F, Levy A, et al. Mechanical stress and prostaglandin E2 syn- thesis in cartilage. Biorheology. 2008;45 (3-4):301-20. 85. Laufer S. Role of eicosanoids in structural degradation in osteoarthritis. Curr Opin Rheumatol. 2003 Sep;15(5):623-7. 86. Marcouiller P, Pelletier JP, Guevremont M, et al. Leukotriene and prostaglandin synthesis pathways in osteoarthritic synovial membranes: regulating factors for interleukin 1beta synthesis. J Rheumatol. 2005 Apr;32(4):704-12. 87. Martel-Pelletier J, Mineau F, Fahmi H, et al. Regulation of the expression of 5-lipoxyge- nase-activating protein/5-lipoxygenase and the synthesis of leukotriene B(4) in osteoarthritic chondrocytes: role of trans- forming growth factor beta and eicosanoids. |